Fosinopril analogs for the treatment of human babesiosis

福辛普利类似物用于治疗人类巴贝虫病

基本信息

  • 批准号:
    10396069
  • 负责人:
  • 金额:
    $ 72.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-21 至 2026-03-31
  • 项目状态:
    未结题

项目摘要

Babesiosis is a malaria-like illness found worldwide and endemic in the United States. The disease is caused by intraerythrocytic parasites of the genus Babesia. Babesia microti and Babesia duncani, which are responsible for most cases reported in the United States, are transmitted to humans by Ixodes scapularis and Dermacentor albipictus ticks, respectively, and can also be introduced by blood transfusion. The current treatment for human babesiosis consists of combination therapies with atovaquone+azithromycin or clindamycin+quinine. However, these drugs are associated with high rate of recrudescence, treatment failures and adverse events. Furthermore, recent studies in mice infected with B. microti and in vitro with B. duncani showed that these parasites are naturally tolerant to these drugs. These limitations emphasize the need for more effective and safer therapies for treatment of human babesiosis. We have recently reported the development of a continuous in vitro culture system for B. duncani in human red blood cells. Using this assay, we screened a library of FDA-approved drugs and identified fosinopril (the prodrug of the dipeptidyl carboxypeptidase ACE inhibitor fosinoprilat) as a potent antibabesial inhibitor. The compound was also effective against both B. duncani and B. microti in mouse models of babesiosis at 10 mg/kg. Interestingly, neither fosinoprilat nor other ACE inhibitors affected the growth of B. duncani in vitro. Equally interesting, analysis of the structure of fosinopril and bortezomib (another potent inhibitor of B. duncani identified in the chemical screen and a known proteasome inhibitor) revealed similarities between the two compounds. Together these data suggest that the antibabesial activity of fosinopril could be due to inhibition of either an ACE-like peptidase and/or a proteasome activity of Babesia parasites. The primary goals of this application are to identify analogs of fosinopril with more potent antibabesial but no ACE activity, and to elucidate the mechanism of action of these compounds in Babesia parasites. Building upon our preliminary data, we propose the following three specific aims. In Aim 1, we will determine whether or not the prodrug form of fosinopril is the active compound, and characterize the efficacy of fosinopril and newly synthesized analogs against B. duncani and B. microti clinical and field isolates in vitro and examine the structure activity relationship specific to these parasites. In Aim 2, we will characterize the in vivo efficacy of the most active compounds alone or in combination with other drugs as a strategy for elimination of Babesia infections. In Aim 3, we will implement biochemical, mass spectrometry and genetic assays to elucidate the mode of action of and possible mechanisms of Babesia resistance to fosinopril and its analogs. The success of the proposed three aims will guide future clinical trials to create an ideal regimen for the treatment of human babesiosis with no recrudescence.
巴贝斯虫病是一种类似疟疾的疾病,在世界范围内发现,在美国流行。这种疾病是由 红细胞内寄生虫引起的巴贝氏田鼠和邓肯巴贝氏田鼠 造成美国报告的大多数病例,由肩突硬蜱传播给人类, 白纹革蜱分别也可通过输血传入。当前 用于人巴贝虫病的治疗包括阿托伐醌+阿奇霉素或 克林霉素+奎宁。然而,这些药物与高复发率,治疗失败 和不良事件。此外,最近在感染B.用B.敦卡尼 表明这些寄生虫对这些药物具有天然耐受性。这些限制强调了以下需要: 用于治疗人类巴贝虫病的更有效和更安全的疗法。我们最近报道了 建立了B的体外连续培养体系。人体红细胞中的邓肯尼使用该测定, 我们筛选了FDA批准的药物库,并鉴定了福辛普利(二肽基的前体药物), 羧肽酶ACE抑制剂福辛普利拉)作为有效的抗巴贝斯虫抑制剂。该化合物还 对B都有效。duncani和B.在10 mg/kg的巴贝斯虫病小鼠模型中的microti。有趣的是, 福辛普利拉和其他ACE抑制剂均不影响B的生长。Duncani in Vitro.同样有趣的是, 福辛普利和硼替佐米(另一种有效的B.邓肯尼在 化学筛选和已知的蛋白酶体抑制剂)揭示了两种化合物之间的相似性。 总之,这些数据表明福辛普利的抗巴贝斯虫活性可能是由于抑制 巴氏疟原虫的ACE样肽酶和/或蛋白酶体活性。此应用程序的主要目标 目的是鉴定福辛普利的类似物,其具有更有效的抗巴贝西而无ACE活性,并阐明 这些化合物在巴贝虫寄生虫中的作用机制。根据我们的初步数据,我们 提出以下三个具体目标。在目的1中,我们将确定化合物1的前药形式是否为 福辛普利是活性化合物,并表征福辛普利和新合成的类似物的功效 对抗B。duncani和B.对临床和田间分离物进行体外分离,并检测结构活性 与这些寄生虫的关系在目标2中,我们将表征最有效的药物组合物的体内功效。 本发明提供了单独或与其它药物组合的化合物作为消除巴氏杆菌感染的策略。在Aim中 3.我们会进行生化、质谱及基因化验,以阐明 以及巴贝妥对福辛普利及其类似物耐药的可能机制。建议的成功 三个目标将指导未来的临床试验,以创造一种理想的治疗人类巴贝斯虫病的方案, 没有复发

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHOUKRI BEN MAMOUN其他文献

CHOUKRI BEN MAMOUN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHOUKRI BEN MAMOUN', 18)}}的其他基金

Fosinopril analogs for the treatment of human babesiosis
福辛普利类似物用于治疗人类巴贝虫病
  • 批准号:
    10211812
  • 财政年份:
    2021
  • 资助金额:
    $ 72.59万
  • 项目类别:
Fosinopril analogs for the treatment of human babesiosis
福辛普利类似物用于治疗人类巴贝虫病
  • 批准号:
    10594970
  • 财政年份:
    2021
  • 资助金额:
    $ 72.59万
  • 项目类别:
Antigen Discovery and Vaccine Development for Human Babesia Parasites
人类巴贝虫寄生虫的抗原发现和疫苗开发
  • 批准号:
    10386919
  • 财政年份:
    2020
  • 资助金额:
    $ 72.59万
  • 项目类别:
Antigen Discovery and Vaccine Development for Human Babesia Parasites
人类巴贝虫寄生虫的抗原发现和疫苗开发
  • 批准号:
    10163799
  • 财政年份:
    2020
  • 资助金额:
    $ 72.59万
  • 项目类别:
Antigen Discovery and Vaccine Development for Human Babesia Parasites
人类巴贝虫寄生虫的抗原发现和疫苗开发
  • 批准号:
    10609400
  • 财政年份:
    2020
  • 资助金额:
    $ 72.59万
  • 项目类别:
Hit-to-Lead Development of the Kalihinol Scaffold for Malaria Treatment
用于疟疾治疗的 Kalihinol 支架的 Hit-to-Lead 开发
  • 批准号:
    9789813
  • 财政年份:
    2018
  • 资助金额:
    $ 72.59万
  • 项目类别:
Hit-to-Lead Development of the Kalihinol Scaffold for Malaria Treatment
用于疟疾治疗的 Kalihinol 支架的 Hit-to-Lead 开发
  • 批准号:
    10228612
  • 财政年份:
    2018
  • 资助金额:
    $ 72.59万
  • 项目类别:
Development of endochin-like quinolones for babesiosis therapy
用于治疗巴贝虫病的类内啡肽喹诺酮类药物的开发
  • 批准号:
    9392521
  • 财政年份:
    2016
  • 资助金额:
    $ 72.59万
  • 项目类别:
Probing the natural genomic diversity of Babesia microti
探究田鼠巴贝虫的自然基因组多样性
  • 批准号:
    9064063
  • 财政年份:
    2015
  • 资助金额:
    $ 72.59万
  • 项目类别:
Development of novel therapeutics for Babesia microti infection
田鼠巴贝虫感染新疗法的开发
  • 批准号:
    8865547
  • 财政年份:
    2014
  • 资助金额:
    $ 72.59万
  • 项目类别:

相似海外基金

How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.59万
  • 项目类别:
    Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 72.59万
  • 项目类别:
    Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 72.59万
  • 项目类别:
    Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.59万
  • 项目类别:
    Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 72.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.59万
  • 项目类别:
    Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 72.59万
  • 项目类别:
    Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 72.59万
  • 项目类别:
    Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
  • 批准号:
    23K00129
  • 财政年份:
    2023
  • 资助金额:
    $ 72.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
  • 批准号:
    2883985
  • 财政年份:
    2023
  • 资助金额:
    $ 72.59万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了